NL-OMON45251
Not yet recruiting
Not Applicable
Comparing tumour heterogeneity in primary tumour, circulating tumour cells and its metastases - CTC Autopsy study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- lungcancer
- Sponsor
- niversitair Medisch Centrum Groningen
- Enrollment
- 50
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients with a histologically/cytologically proven lung cancer.
- •2\. Patients have to have a non\-curable disease state, without curative treatment options
- •3\. Signed informed consent of patient
- •4\. Patients family has asserted their acceptance of the patients participation
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Not Applicable
Comparing tumour heterogeneity in primary tumour, circulating tumour cells and metastasesSCLC niet kleincellig longcarcinoom, longkankerlungcancer, tumour heterogeneity, tumor heterogeniteit, CTC, circulating tumour cell, circulerende tumor celNL-OMON29203niversity Medical Centre Groningen30
Recruiting
Not Applicable
Characterisation of tumour heterogeneity and identification of adaptive resistance mechanisms of metastatic castration-resistant prostate carcinomaC61Malignant neoplasm of prostateDRKS00028021Klinik für Nuklearmedizin am Universitätsklinikum Augsburg45
Not yet recruiting
Phase 1/2
Tumour heterogeneity studies based on dedicated breast PET using proliferation radiotracers: early detection of the treatment response.2024-512152-38-00Fundacion Instituto De Investigacion Sanitaria De Santiago De Compostela100
Not yet recruiting
Not Applicable
Fluorodeoxyglucose (FDG) and human epidermal growth factor receptor 2 (HER2) positron emission tomography (PET) scan in breast cancerBreast cancerCancer - BreastACTRN12624000918527Fiona Stanley Hospital10
Recruiting
Not Applicable
Value of 7 Tesla in gliomasHigh grade and low grade gliomaNL-OMON24352Medical Delta25